Pfizer slides as 2026 revenue is seen pressured by patent cliffs
Pfizer shares fell in premarket trading after reaffirming its 2026 outlook, projecting roughly a $1.5 billion revenue decline as products lose market exclusivity. The headwind is driven by patent cliffs, tariffs, and about $5 billion in COVID-19 product revenue, even as vaccines and drugs such as Abrysvo, Eliquis, Padcev, and Prevnar show growth.